[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Joshua Aiello, Principal Accounting Officer at Orchestra BioMed Holdings, Inc. (OBIO), reported an award of 15,000 restricted stock units (RSUs) on August 7, 2025. Each RSU represents a contingent right to one share of common stock and the grant lists a $0 per-share price. The RSUs vest in three tranches over three years: 33.33% vest 24 months after the grant date, 33.33% vest 30 months after the grant date, and 33.34% vest 36 months after the grant date, subject to continuous service. The Form 4 shows 19,329 shares as beneficially owned following the reported transaction and is signed by an attorney-in-fact on August 8, 2025.
Joshua Aiello, Responsabile principale della contabilit脿 di Orchestra BioMed Holdings, Inc. (OBIO), ha ricevuto l'assegnazione di 15.000 unit脿 di azioni vincolate (RSU) il 7 agosto 2025. Ogni RSU corrisponde al diritto condizionale a una azione ordinaria e l'assegnazione indica un prezzo per azione di $0. Le RSU maturano in tre tranche nell'arco di tre anni: il 33,33% matura 24 mesi dopo la data di assegnazione, il 33,33% a 30 mesi e il 33,34% a 36 mesi, subordinatamente alla continuit脿 del servizio. Il Modulo 4 indica 19.329 azioni come detenute a titolo beneficiario dopo la transazione segnalata ed 猫 firmato da un mandatario con procura l'8 agosto 2025.
Joshua Aiello, director principal de contabilidad de Orchestra BioMed Holdings, Inc. (OBIO), inform贸 la concesi贸n de 15.000 unidades restringidas de acciones (RSU) el 7 de agosto de 2025. Cada RSU otorga el derecho condicional a una acci贸n ordinaria y la concesi贸n indica un precio por acci贸n de $0. Las RSU se consolidan en tres tramos durante tres a帽os: el 33,33% se consolida 24 meses despu茅s de la fecha de concesi贸n, otro 33,33% a los 30 meses y el 33,34% a los 36 meses, sujeto a servicio continuo. El Formulario 4 muestra 19.329 acciones como propiedad beneficiaria tras la transacci贸n informada y est谩 firmado por un apoderado el 8 de agosto de 2025.
Orchestra BioMed Holdings, Inc.(OBIO)鞚� 靾橃劃 須岅硠 毂呾瀯鞛� Joshua Aiello電� 2025雲� 8鞗� 7鞚检棎 15,000欤检潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 靾橃棳氚涭晿雼り碃 氤搓碃頄堨姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 攵�鞐� 氍胳劀鞐愲姅 欤茧嫻 臧�瓴╈澊 $0搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. RSU電� 3雲勳棎 瓯胳硱 靹� 氩堨棎 雮橂垊鞏� 旆摑霅橂┌, 33.33%電� 攵�鞐澕搿滊秬韯� 24臧滌洈 頉�, 33.33%電� 30臧滌洈 頉�, 33.34%電� 36臧滌洈 頉勳棎 臧侁皝 旆摑霅橂┌ 瓿勳啀 攴茧臧� 臁瓣贝鞛呺媹雼�. Form 4鞐愲姅 氤搓碃霅� 瓯半灅 鞚错泟 19,329欤缄皜 靾橃澋鞝侅溂搿� 氤挫湢霅� 瓴冹溂搿� 響滌嫓霅橃柎 鞛堦碃, 2025雲� 8鞗� 8鞚检棎 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Joshua Aiello, responsable principal de la comptabilit茅 chez Orchestra BioMed Holdings, Inc. (OBIO), a d茅clar茅 l'attribution de 15 000 unit茅s d'actions restreintes (RSU) le 7 ao没t 2025. Chaque RSU repr茅sente le droit conditionnel 脿 une action ordinaire et l'attribution indique un prix unitaire de 0 $. Les RSU se r茅partissent en trois tranches sur trois ans : 33,33 % deviennent acquis 24 mois apr猫s la date d'attribution, 33,33 % 脿 30 mois et 33,34 % 脿 36 mois, sous r茅serve d'une continuit茅 de service. Le formulaire 4 indique que 19 329 actions sont d茅tenues 脿 titre b茅n茅ficiaire 脿 la suite de la transaction signal茅e et il est sign茅 par un mandataire le 8 ao没t 2025.
Joshua Aiello, leitender Rechnungslegungsverantwortlicher von Orchestra BioMed Holdings, Inc. (OBIO), meldete am 7. August 2025 eine Zuteilung von 15.000 Restricted Stock Units (RSU). Jede RSU gew盲hrt das bedingte Recht auf eine Stammaktie, und die Zuteilung weist einen Aktienst眉ckpreis von $0 aus. Die RSUs werden 眉ber drei Jahre in drei Tranchen f盲llig: 33,33 % werden 24 Monate nach dem Zuteilungsdatum f盲llig, 33,33 % nach 30 Monaten und 33,34 % nach 36 Monaten, jeweils vorbehaltlich fortlaufender Dienstzeit. Das Formular 4 weist nach der gemeldeten Transaktion 19.329 als wirtschaftlich gehaltene Aktien aus und wurde am 8. August 2025 von einem Bevollm盲chtigten unterzeichnet.
- None.
- None.
Insights
TL;DR: Routine executive equity grant of 15,000 RSUs to the company鈥檚 principal accounting officer; disclosure appears standard and non-material.
The filing documents a time鈥慴ased equity award to align the reporting person with shareholder interests. The award is structured as RSUs at $0 with a clearly defined three鈥憏ear vesting schedule. The Form 4 also reports 19,329 shares beneficially owned after the grant. There is no indication of accelerated vesting, sales, or related-party transfers. From a market鈥慽mpact perspective, the grant is typical compensation disclosure without immediate dilution or cash transfer.
TL;DR: Compensation disclosure follows standard Form 4 practice; vesting terms are time鈥慴ased and subject to continued service.
The report identifies the recipient as Principal Accounting Officer and provides the grant date, unit count, and precise vesting milestones, which supports transparency around executive incentives. The signature by an attorney鈥慽n鈥慺act is noted and the filing includes the resulting beneficial ownership total. Absent additional context on company capitalization or related insider transactions, this appears to be a routine equity compensation event rather than a governance concern.
Joshua Aiello, Responsabile principale della contabilit脿 di Orchestra BioMed Holdings, Inc. (OBIO), ha ricevuto l'assegnazione di 15.000 unit脿 di azioni vincolate (RSU) il 7 agosto 2025. Ogni RSU corrisponde al diritto condizionale a una azione ordinaria e l'assegnazione indica un prezzo per azione di $0. Le RSU maturano in tre tranche nell'arco di tre anni: il 33,33% matura 24 mesi dopo la data di assegnazione, il 33,33% a 30 mesi e il 33,34% a 36 mesi, subordinatamente alla continuit脿 del servizio. Il Modulo 4 indica 19.329 azioni come detenute a titolo beneficiario dopo la transazione segnalata ed 猫 firmato da un mandatario con procura l'8 agosto 2025.
Joshua Aiello, director principal de contabilidad de Orchestra BioMed Holdings, Inc. (OBIO), inform贸 la concesi贸n de 15.000 unidades restringidas de acciones (RSU) el 7 de agosto de 2025. Cada RSU otorga el derecho condicional a una acci贸n ordinaria y la concesi贸n indica un precio por acci贸n de $0. Las RSU se consolidan en tres tramos durante tres a帽os: el 33,33% se consolida 24 meses despu茅s de la fecha de concesi贸n, otro 33,33% a los 30 meses y el 33,34% a los 36 meses, sujeto a servicio continuo. El Formulario 4 muestra 19.329 acciones como propiedad beneficiaria tras la transacci贸n informada y est谩 firmado por un apoderado el 8 de agosto de 2025.
Orchestra BioMed Holdings, Inc.(OBIO)鞚� 靾橃劃 須岅硠 毂呾瀯鞛� Joshua Aiello電� 2025雲� 8鞗� 7鞚检棎 15,000欤检潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 靾橃棳氚涭晿雼り碃 氤搓碃頄堨姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 攵�鞐� 氍胳劀鞐愲姅 欤茧嫻 臧�瓴╈澊 $0搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. RSU電� 3雲勳棎 瓯胳硱 靹� 氩堨棎 雮橂垊鞏� 旆摑霅橂┌, 33.33%電� 攵�鞐澕搿滊秬韯� 24臧滌洈 頉�, 33.33%電� 30臧滌洈 頉�, 33.34%電� 36臧滌洈 頉勳棎 臧侁皝 旆摑霅橂┌ 瓿勳啀 攴茧臧� 臁瓣贝鞛呺媹雼�. Form 4鞐愲姅 氤搓碃霅� 瓯半灅 鞚错泟 19,329欤缄皜 靾橃澋鞝侅溂搿� 氤挫湢霅� 瓴冹溂搿� 響滌嫓霅橃柎 鞛堦碃, 2025雲� 8鞗� 8鞚检棎 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Joshua Aiello, responsable principal de la comptabilit茅 chez Orchestra BioMed Holdings, Inc. (OBIO), a d茅clar茅 l'attribution de 15 000 unit茅s d'actions restreintes (RSU) le 7 ao没t 2025. Chaque RSU repr茅sente le droit conditionnel 脿 une action ordinaire et l'attribution indique un prix unitaire de 0 $. Les RSU se r茅partissent en trois tranches sur trois ans : 33,33 % deviennent acquis 24 mois apr猫s la date d'attribution, 33,33 % 脿 30 mois et 33,34 % 脿 36 mois, sous r茅serve d'une continuit茅 de service. Le formulaire 4 indique que 19 329 actions sont d茅tenues 脿 titre b茅n茅ficiaire 脿 la suite de la transaction signal茅e et il est sign茅 par un mandataire le 8 ao没t 2025.
Joshua Aiello, leitender Rechnungslegungsverantwortlicher von Orchestra BioMed Holdings, Inc. (OBIO), meldete am 7. August 2025 eine Zuteilung von 15.000 Restricted Stock Units (RSU). Jede RSU gew盲hrt das bedingte Recht auf eine Stammaktie, und die Zuteilung weist einen Aktienst眉ckpreis von $0 aus. Die RSUs werden 眉ber drei Jahre in drei Tranchen f盲llig: 33,33 % werden 24 Monate nach dem Zuteilungsdatum f盲llig, 33,33 % nach 30 Monaten und 33,34 % nach 36 Monaten, jeweils vorbehaltlich fortlaufender Dienstzeit. Das Formular 4 weist nach der gemeldeten Transaktion 19.329 als wirtschaftlich gehaltene Aktien aus und wurde am 8. August 2025 von einem Bevollm盲chtigten unterzeichnet.
FAQ
What did Joshua Aiello report on Form 4 (OBIO)?
How do the RSUs awarded to the OBIO officer vest?
What is the beneficial ownership after the reported transaction in the OBIO Form 4?
What price was reported for the RSU award on the OBIO Form 4?
When was the Form 4 transaction dated and who signed the filing?
